Author:
King Emily A.,Davis J. Wade,Degner Jacob F.
Abstract
1AbstractDespite strong vetting for disease activity, only 10% of candidate new molecular entities in early stage clinical trials are eventually approved. Analyzing historical pipeline data, Nelson et al. 2015 (Nat. Genet.) concluded pipeline drug targets with human genetic evidence of disease association are twice as likely to lead to approved drugs. Taking advantage of recent clinical development advances and rapid growth in GWAS datasets, we extend the original work using updated data, test whether genetic evidence predicts future successes and introduce statistical models adjusting for target and indication-level properties. Our work confirms drugs with genetically supported targets were more likely to be successful in Phases II and III. When causal genes are clear (Mendelian traits and GWAS associations linked to coding variants), we find the use of human genetic evidence increases approval from Phase I by greater than two-fold, and, for Mendelian associations, the positive association holds prospectively. Our findings suggest investments into genomics and genetics are likely to be beneficial to companies deploying this strategy.
Publisher
Cold Spring Harbor Laboratory
Reference34 articles.
1. Informa’s pharmaprojects. https://pharmaintelligence.informa.com/products-and-services/data-and-analysis/pharmaprojects. Accessed: 2018-01-25.
2. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
3. Tomas J. Aragon . epitools: Epidemiology Tools, 2017. R package version 0.5-10.
4. Efficient and scalable scaffolding using optical restriction maps
5. Winston Chang , Joe Cheng , JJ Allaire , Yihui Xie , and Jonathan McPherson . shiny: Web Application Frame-work for R, 2018. R package version 1.2.0.
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献